A founder of the field of synthetic biology is selling data from his own DNA as a nonfungible token, or NFT, through Nebula Genomics, a personal genome company he cofounded.
Scientists have raised questions about the dataset published in The Lancet last week that triggered the suspension of clinical trials around the world—and about Surgisphere Corporation, the company behind the study.
A security researcher found the email addresses and encrypted passwords of more than 92 million users of the genealogy site on a private server outside the company.
Luna DNA, Nebula Genomics, and other “bio-brokers” will allow customers to make money by granting access to their genetic and personal information for research purposes.
In a defamation lawsuit involving anonymous comments on the post-publication peer review website, a judge requests potentially identifying information.
Four UK research funding agencies firm up their stance against deliberate attempts by researchers to re-identify supposedly anonymous study participants.